PMC:7319919 / 5592-6155 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T23","span":{"begin":269,"end":273},"obj":"Body_part"},{"id":"T24","span":{"begin":358,"end":363},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T32","span":{"begin":68,"end":101},"obj":"Disease"},{"id":"T33","span":{"begin":196,"end":204},"obj":"Disease"},{"id":"T34","span":{"begin":442,"end":450},"obj":"Disease"},{"id":"T35","span":{"begin":453,"end":462},"obj":"Disease"},{"id":"T36","span":{"begin":554,"end":562},"obj":"Disease"}],"attributes":[{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T60","span":{"begin":22,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T61","span":{"begin":51,"end":59},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T62","span":{"begin":228,"end":232},"obj":"http://purl.obolibrary.org/obo/CLO_0053407"},{"id":"T63","span":{"begin":263,"end":268},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T64","span":{"begin":269,"end":273},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T65","span":{"begin":358,"end":363},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T45","span":{"begin":13,"end":21},"obj":"Chemical"},{"id":"T46","span":{"begin":41,"end":50},"obj":"Chemical"},{"id":"T47","span":{"begin":398,"end":406},"obj":"Chemical"},{"id":"T48","span":{"begin":517,"end":526},"obj":"Chemical"},{"id":"T49","span":{"begin":546,"end":550},"obj":"Chemical"}],"attributes":[{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_45783"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_45783"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"147","span":{"begin":139,"end":152},"obj":"Species"},{"id":"148","span":{"begin":196,"end":206},"obj":"Species"},{"id":"149","span":{"begin":334,"end":347},"obj":"Species"},{"id":"150","span":{"begin":13,"end":21},"obj":"Chemical"},{"id":"151","span":{"begin":398,"end":406},"obj":"Chemical"},{"id":"152","span":{"begin":442,"end":462},"obj":"Disease"},{"id":"153","span":{"begin":554,"end":562},"obj":"Disease"}],"attributes":[{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"Tax:11118"},{"id":"A148","pred":"tao:has_database_id","subj":"148","obj":"Tax:2697049"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"Tax:11118"},{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"MESH:D000068877"},{"id":"A151","pred":"tao:has_database_id","subj":"151","obj":"MESH:D000068877"},{"id":"A152","pred":"tao:has_database_id","subj":"152","obj":"MESH:C000657245"},{"id":"A153","pred":"tao:has_database_id","subj":"153","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T11","span":{"begin":269,"end":280},"obj":"http://purl.obolibrary.org/obo/GO_0140253"},{"id":"T12","span":{"begin":269,"end":280},"obj":"http://purl.obolibrary.org/obo/GO_0045026"},{"id":"T13","span":{"begin":269,"end":280},"obj":"http://purl.obolibrary.org/obo/GO_0000768"},{"id":"T14","span":{"begin":269,"end":280},"obj":"http://purl.obolibrary.org/obo/GO_0000747"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T43","span":{"begin":0,"end":212},"obj":"Sentence"},{"id":"T44","span":{"begin":213,"end":368},"obj":"Sentence"},{"id":"T45","span":{"begin":369,"end":563},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T76","span":{"begin":13,"end":21},"obj":"CHEBI:14434;CHEBI:14434"},{"id":"T77","span":{"begin":81,"end":92},"obj":"UBERON:0001004"},{"id":"T78","span":{"begin":118,"end":129},"obj":"UBERON:0001004"},{"id":"T79","span":{"begin":139,"end":152},"obj":"NCBITaxon:11118"},{"id":"T80","span":{"begin":196,"end":206},"obj":"SP_7"},{"id":"T81","span":{"begin":228,"end":232},"obj":"PR:000003583"},{"id":"T82","span":{"begin":263,"end":268},"obj":"NCBITaxon:10239"},{"id":"T83","span":{"begin":269,"end":280},"obj":"GO:0061025"},{"id":"T84","span":{"begin":312,"end":320},"obj":"GO:0065007"},{"id":"T85","span":{"begin":334,"end":347},"obj":"NCBITaxon:11118"},{"id":"T86","span":{"begin":398,"end":406},"obj":"CHEBI:14434;CHEBI:14434"},{"id":"T87","span":{"begin":442,"end":452},"obj":"SP_7"},{"id":"T88","span":{"begin":546,"end":550},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T89","span":{"begin":554,"end":562},"obj":"SP_7"},{"id":"T45081","span":{"begin":13,"end":21},"obj":"CHEBI:14434;CHEBI:14434"},{"id":"T88775","span":{"begin":81,"end":92},"obj":"UBERON:0001004"},{"id":"T61507","span":{"begin":118,"end":129},"obj":"UBERON:0001004"},{"id":"T25185","span":{"begin":139,"end":152},"obj":"NCBITaxon:11118"},{"id":"T11544","span":{"begin":196,"end":206},"obj":"SP_7"},{"id":"T8102","span":{"begin":228,"end":232},"obj":"PR:000003583"},{"id":"T86755","span":{"begin":263,"end":268},"obj":"NCBITaxon:10239"},{"id":"T99959","span":{"begin":269,"end":280},"obj":"GO:0061025"},{"id":"T94733","span":{"begin":312,"end":320},"obj":"GO:0065007"},{"id":"T61456","span":{"begin":334,"end":347},"obj":"NCBITaxon:11118"},{"id":"T8366","span":{"begin":398,"end":406},"obj":"CHEBI:14434;CHEBI:14434"},{"id":"T88154","span":{"begin":442,"end":452},"obj":"SP_7"},{"id":"T36497","span":{"begin":546,"end":550},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T63516","span":{"begin":554,"end":562},"obj":"SP_7"}],"text":"In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19."}